According to Zacks, “NantKwest, Inc. is a clinical-stage immunotherapy company. The Company’s product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California. “
Several other research analysts also recently commented on NK. Piper Jaffray Cos. reissued an overweight rating and issued a $23.00 price objective (down from $32.00) on shares of NantKwest in a research note on Wednesday, August 17th. Canaccord Genuity reissued a buy rating and issued a $18.00 price objective on shares of NantKwest in a research note on Friday, August 19th. Finally, Raymond James Financial Inc. started coverage on NantKwest in a research note on Thursday, June 2nd. They issued a market perform rating for the company. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $17.40.
Shares of NantKwest (NASDAQ:NK) opened at 7.59 on Wednesday. The company’s market capitalization is $624.74 million. NantKwest has a 52-week low of $5.43 and a 52-week high of $19.43. The stock’s 50 day moving average price is $8.04 and its 200 day moving average price is $7.66.
In other NantKwest news, insider Barry J. Simon sold 32,000 shares of the company’s stock in a transaction on Thursday, September 8th. The stock was sold at an average price of $7.49, for a total value of $239,680.00. Following the completion of the sale, the insider now directly owns 3,334,906 shares in the company, valued at approximately $24,978,445.94. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 73.06% of the stock is owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in NantKwest by 13.9% in the second quarter. Vanguard Group Inc. now owns 1,583,285 shares of the company’s stock worth $9,848,000 after buying an additional 193,338 shares in the last quarter. BlackRock Fund Advisors boosted its position in NantKwest by 18.5% in the second quarter. BlackRock Fund Advisors now owns 1,449,408 shares of the company’s stock worth $9,015,000 after buying an additional 226,513 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in NantKwest by 30.6% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 244,539 shares of the company’s stock worth $1,521,000 after buying an additional 57,321 shares in the last quarter. JPMorgan Chase & Co. boosted its position in NantKwest by 2.2% in the first quarter. JPMorgan Chase & Co. now owns 152,196 shares of the company’s stock worth $1,251,000 after buying an additional 3,309 shares in the last quarter. Finally, State Street Corp boosted its position in NantKwest by 8.5% in the second quarter. State Street Corp now owns 135,270 shares of the company’s stock worth $843,000 after buying an additional 10,640 shares in the last quarter. Institutional investors and hedge funds own 24.13% of the company’s stock.
NantKwest, Inc, formerly Conkwest, Inc, is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related companies with MarketBeat.com's FREE daily email newsletter.